Prescription ·Strong evidence ·Reviewed May 2026
Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for type 2 diabetes and to reduce cardiovascular death in patients with established cardiovascular disease. It also has FDA approval for heart failure with reduced ejection fraction. The EMPA-REG OUTCOME trial demonstrated significant cardiovascular mortality benefit.
The bottom line
Evidence rating strong. Most-documented uses: lowers hba1c by 0.5–0.8%, significant cardiovascular mortality reduction (38% in empa-reg outcome), heart failure hospitalization reduction. 9 sources indexed (2024–2026), with 3 interaction records on file.
Core mechanism
Selectively and reversibly inhibits the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, which is responsible for approximately 90% of renal glucose reabsorption. This reduces the renal glucose threshold and causes glycosuria (urinary glucose excretion of 60–80 g/day), lowering plasma glucose independent of insulin. Secondary effects include osmotic diuresis, natriuresis, blood pressure reduction, and weight loss.
Can be taken with or without food. Best taken in the morning to minimize nocturia.
Both empagliflozin and berberine lower blood glucose through different mechanisms. Combined use may increase hypoglycemia risk, particularly when combined with insulin or sulfonylureas.
Recommendation: Monitor blood glucose when combining. The risk is lower than with sulfonylureas but still clinically relevant, especially in patients on multiple glucose-lowering agents.
Empagliflozin lowers blood glucose by causing urinary glucose excretion. Chromium independently improves insulin sensitivity. Used together the additive glucose-lowering is usually mild because SGLT2 inhibitors rarely cause hypoglycemia alone, but the risk rises when empagliflozin is part of a multi-drug regimen that already includes insulin or a sulfonylurea.
Recommendation: If your only diabetes medication is empagliflozin, chromium can be added with home glucose monitoring during the first 2-4 weeks. If you also take insulin or a sulfonylurea, talk to your prescriber first about a dose reduction.
Alpha-lipoic acid improves insulin sensitivity and lowers fasting glucose, while empagliflozin causes urinary glucose excretion. On empagliflozin alone the hypoglycemia risk is low, but additive glucose-lowering matters when ALA is added on top of insulin or a sulfonylurea. ALA has also rarely triggered insulin autoimmune syndrome with severe hypoglycemia.
Recommendation: If empagliflozin is your only diabetes medication, ALA can be added with home glucose monitoring for the first 2-4 weeks. If you also take insulin or a sulfonylurea, ask your prescriber whether the other agent needs a dose reduction first.
Numbered references. Citations throughout the page link here.
Saleem T, Rasool MF, Saeed H et al.. Exploring the clinical pharmacokinetics and pharmacodynamics of SGLT2 inhibitor, empagliflozin: a systematic review. Drug metabolism reviews. 2026
Matteucci A, Pandozi C, Bonanni M et al.. Impact of empagliflozin and dapagliflozin on sudden cardiac death: A systematic review and meta-analysis of adjudicated randomized evidence. Heart rhythm. 2025
Khalid N, Afzal MA, Abdullah M et al.. Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis. Future cardiology. 2025
Hamid AK, Tayem AA, Al-Aish ST et al.. Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. Therapeutic advances in cardiovascular disease. 2024
Yan Q, Chen X, Yu C et al.. Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis. BMC cardiovascular disorders. 2024
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack